BR112023020057A2 - Tratamento de dor e distúrbios inflamatórios - Google Patents

Tratamento de dor e distúrbios inflamatórios

Info

Publication number
BR112023020057A2
BR112023020057A2 BR112023020057A BR112023020057A BR112023020057A2 BR 112023020057 A2 BR112023020057 A2 BR 112023020057A2 BR 112023020057 A BR112023020057 A BR 112023020057A BR 112023020057 A BR112023020057 A BR 112023020057A BR 112023020057 A2 BR112023020057 A2 BR 112023020057A2
Authority
BR
Brazil
Prior art keywords
treatment
pain
chain
clostridial neurotoxin
domain
Prior art date
Application number
BR112023020057A
Other languages
English (en)
Inventor
Christine Favre
Cindy Perier
Ahmed Ibrahim Hodan
Caroline Maignel Jacqueline
Johannes Krupp
Mark Elliott
Mikhail Kalinichev
Sylvie Cornet
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2021/050783 external-priority patent/WO2022208039A1/en
Priority claimed from TW110111559A external-priority patent/TW202237176A/zh
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of BR112023020057A2 publication Critical patent/BR112023020057A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

tratamento de dor e distúrbios inflamatórios. a presente invenção é direcionada a um polipeptídeo para uso no tratamento da dor ou de um distúrbio inflamatório, em que o polipeptídeo compreende uma cadeia leve (cadeia l) de neurotoxina clostridial, um domínio de translocação de neurotoxina clostridial (domínio hn) e/ou um domínio de ligação ao receptor de neurotoxina clostridial (domínio hc), em que, quando o polipeptídeo compreende uma cadeia l de neurotoxina clostridial, a cadeia l é cataliticamente inativa. também são fornecidos métodos de tratamento e usos correspondentes.
BR112023020057A 2021-03-30 2022-03-30 Tratamento de dor e distúrbios inflamatórios BR112023020057A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2021/050783 WO2022208039A1 (en) 2021-03-30 2021-03-30 Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
TW110111559A TW202237176A (zh) 2021-03-30 2021-03-30 疼痛及發炎性失調之治療
PCT/GB2022/050807 WO2022208091A1 (en) 2021-03-30 2022-03-30 Treatment of pain & inflammatory disorders

Publications (1)

Publication Number Publication Date
BR112023020057A2 true BR112023020057A2 (pt) 2024-03-12

Family

ID=83458127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020057A BR112023020057A2 (pt) 2021-03-30 2022-03-30 Tratamento de dor e distúrbios inflamatórios

Country Status (7)

Country Link
EP (1) EP4313120A1 (pt)
JP (1) JP2024513191A (pt)
KR (1) KR20230163470A (pt)
AU (1) AU2022247196A1 (pt)
BR (1) BR112023020057A2 (pt)
CA (1) CA3213914A1 (pt)
WO (1) WO2022208091A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022392458A1 (en) * 2021-11-22 2024-05-02 Ipsen Biopharm Limited Treatment of pain
WO2024069191A1 (en) * 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
PL201879B1 (pl) 1998-05-13 2009-05-29 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Białko hybrydowe i jego zastosowanie
EP1346731B1 (en) 1998-07-22 2006-12-06 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
EP1206554B2 (en) 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
WO2006059093A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK1926744T4 (en) 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
AU2007272517B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
SG11201407784UA (en) 2012-05-30 2014-12-30 Harvard College Engineered botulinum neurotoxin
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP3822286A1 (en) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
US11268080B2 (en) 2015-03-26 2022-03-08 President And Fellows Of Harvard College Engineered botulinum neurotoxin
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PL3481852T3 (pl) 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
CA3220194A1 (en) 2018-01-29 2019-08-01 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
KR20200115584A (ko) * 2018-01-30 2020-10-07 칠드런'즈 메디컬 센터 코포레이션 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220220466A1 (en) * 2019-04-17 2022-07-14 Children's Medical Center Corporation Catalytically inactive botulinum neurotoxin-like toxins and uses thereof

Also Published As

Publication number Publication date
AU2022247196A1 (en) 2023-10-05
AU2022247196A9 (en) 2024-02-22
JP2024513191A (ja) 2024-03-22
KR20230163470A (ko) 2023-11-30
CA3213914A1 (en) 2022-10-06
WO2022208091A1 (en) 2022-10-06
EP4313120A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
BR112023020057A2 (pt) Tratamento de dor e distúrbios inflamatórios
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112022014623A2 (pt) Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
BR112017023849A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos
BR112015013700A2 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112018010673A8 (pt) moléculas de anticorpo para april e seus usos
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112023018473A2 (pt) Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
CL2007003005A1 (es) Compuestos derivados de [1,6]-naftiridinona, moduladores de la actividad cinasa; composicion farmaceutica que los comprende; y su uso para tratar trastornos proliferativos, inflamatorios, autoinmune, del sistema nervioso central, entre otros.
BR112015026258A2 (pt) composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
NO20084792L (no) Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
BR112023022836A2 (pt) Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
BRPI0519808A2 (pt) fluidos ultrapuros
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
BRPI0610454B8 (pt) método para tratar ou prevenir diabetes tipo-2
BR112018012623A2 (pt) catalisador de oxidação para gás de escape de sistema de combustão de gás natural comprimido
BRPI0514836A (pt) uso de toxina botulìnica para tratamento de uma deformidade da nádega
BR112022007851A2 (pt) Anticorpo de domínio único anti-il-4r e uso do mesmo
BR112023024465A2 (pt) Usos de um modulador de somatostatina para o tratamento de doença